Bumjoon Park, PhD

[Career]
▪ Ph.D. in Cell Biology
▪ CEO/CTO of PRG S&Tech Inc., Sep 2017-Present
▪ Professor of Molecular Biology at Pusan National University, Mar 2006-Present
▪ Visitor Scholar, MD Anderson Cancer Center, Aug 2014-Jul 2015
▪ Senior Researcher, Creative Research Center of Protein Synthesis Network at Seoul National University, Mar 2002-Feb 2006

[International Activities]
▪ Member of the Progeria Research Foundation, 2015-Present
▪ Full member of the Korean Molecular Cell Biology Association, 2006-Present
▪ Full member and sponsor of the Korean Society for Biochemistry and Molecular Biology, 2006-Present

[Research Achievements]
▪ Technology transfer: A total of 8 cases (technical fee of $700,000 (KRW 910 million))
▪ Paper: Including 3 representative papers (last 5 years), a total of 79 SCI(E) papers
- Progerinin, an optimized progerin-lamin A binding inhibitor, ameliorates premature senescence phenotypes of Hutchinson-Gilford progeria syndrome. Communications Biology 4.1 (2021): 5. (IF:6.548)
- Novel chemical inhibitor against SOD1 misfolding and aggregation protects neuron-loss and ameliorates disease symptoms in ALS mouse model. Communications Biology 4.1 (2021): 1397.(IF:6.548)
- p53 induces senescence through Lamin A/C stabilization-mediated nuclear deformation. Cell death & disease 10.2 (2019): 107. (IF:9.696)